-
Innovation Ranking
NewInnovation Ranking – Agenus Inc
Agenus Inc (Agenus) is a clinical-stage immuno-oncology company that discovers, develops, and commercializes immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company’s pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company's technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. The company collaborates with several pharmaceutical companies such as...
-
Product Insights
NewNet Present Value Model: Agenus Inc’s Botensilimab
Empower your strategies with our Net Present Value Model: Agenus Inc's Botensilimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Regeneron Pharmaceuticals Inc’s Linvoseltamab
Empower your strategies with our Net Present Value Model: Regeneron Pharmaceuticals Inc's Linvoseltamab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Balstilimab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Balstilimab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Balstilimab in Solid Tumor Drug Details: AGEN-2034 (balstilimab) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Botensilimab in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Botensilimab in Metastatic Renal Cell Carcinoma Drug Details: AGEN-1181...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Balstilimab in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Balstilimab in Oropharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Balstilimab in Oropharyngeal Cancer Drug Details: AGEN-2034 (balstilimab) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Balstilimab in Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Balstilimab in Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Balstilimab in Squamous Cell Carcinoma Drug Details: AGEN-2034 (balstilimab) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Balstilimab in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Balstilimab in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Balstilimab in Metastatic Colorectal Cancer Drug Details: AGEN-2034 (balstilimab) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Botensilimab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Botensilimab in Solid Tumor Drug Details: AGEN-1181 is under development for...